QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 biorestorative-secures-notice-of-allowance-for-japanese-patent-for-thermostem-platform

BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerativ...

 biorestorative-therapies-reveals-1085m-registered-direct-offering-priced-above-market

MELVILLE, N.Y., Oct. 06, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or t...

 biorestorative-therapies-q2-eps-030-beats-037-estimate-sales-303000k-miss-340000k-estimate

BioRestorative Therapies (NASDAQ:BRTX) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate...

 biorestorative-therapies-announces-2m-stock-repurchase-program

BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical st...

 biorestorative-to-present-stem-cell-trial-data-for-back-pain-at-global-conference

BioRestorative Therapies, Inc. ("BioRestorative," "BRTX" or the "Company") (NASDAQ:BRTX), a clinical-st...

 biorestorative-therapies-q1-eps-064-misses-033-estimate-sales-2500k-miss-38000k-estimate

BioRestorative Therapies (NASDAQ:BRTX) reported quarterly losses of $(0.64) per share which missed the analyst consensus estima...

 biorestorative-therapies-presents-preliminary-phase-2-brtx-100-data-at-isct-2025-annual-meeting

BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical st...

 biorestorative-therapies-q4-2024-gaap-eps-020-beats-028-estimate-sales-43300k-miss-475000k-estimate

BioRestorative Therapies (NASDAQ:BRTX) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate...

 biorestorative-announces-fda-clearance-of-ind-for-phase-2-trial-of-brtx-100-in-chronic-cervical-discogenic-pain

– BRTX-100 is the first and only stem cell product candidate cleared to be evaluated in the cervical degenerative disc disease ...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION